HAYA Therapeutics
PrivateLast Round
Series A
May 8, 2025
Total Funding Raised
$91.79M
Company Overview
HAYA Therapeutics operates in Healthcare & Life Sciences and is based in Lausanne. Its latest recorded funding round was a Series A round in May 2025.
HAYA Therapeutics is a biotechnology company developing programmable therapeutics targeting regulatory RNAs to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HAYA Therapeutics Comparables
Compare HAYA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Therorna Inc. | 78% | |
| Eclipsebio | 77% | |
| Harness Therapeutics | 77% |
For institutional investors. Book with your work email.
HAYA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 8, 2025 | ||||
| Grant | Feb 12, 2025 | ||||
| Seed | Feb 9, 2022 | ||||
| Seed | May 20, 2021 | ||||
| Grant | Aug 16, 2018 | ||||
Grant | Feb 2, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HAYA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LifeLink Ventures | Series A |
| 4see ventures | Seed, Series A |
| +ND Capital | Series A |
| Viva BioInnovator | Seed |
| Humboldt Fund | Seed |
| Athos Capital | Series A |
| Viva Biotech | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Lead program HTX-001 advancing for hypertrophic cardiomyopathy treatment.
- Oct 1, 2025
Received the Innosuisse Certificate for Sustainable Growth.
For institutional investors. Book with your work email.
HAYA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HAYA Therapeutics's valuation, stock price, and market status.
Is HAYA Therapeutics a public or private company?
HAYA Therapeutics is a private company.
What is the current stock price of HAYA Therapeutics?
HAYA Therapeutics is a private company, so its shares have no public market price. Caplight tracks HAYA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HAYA Therapeutics worth (valuation)?
Valuation information for HAYA Therapeutics is not publicly available.
Can I buy HAYA Therapeutics stock?
HAYA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HAYA Therapeutics's last funding round?
HAYA Therapeutics's most recent funding round was Series A on May 8, 2025.
Who are the main investors in HAYA Therapeutics?
Key investors in HAYA Therapeutics include Humboldt Fund, Sofinnova Partners, Earlybird Venture Capital, Innosuisse, Broadview Ventures.
Will HAYA Therapeutics IPO soon?
No public IPO plans have been announced for HAYA Therapeutics.
How can I track HAYA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in HAYA Therapeutics's shares on secondary markets.